TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28551590

Group type: EXPERIMENTAL
Intervention: Doxazosin (up to 16mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Higher standing diastolic BP as a moderator
Number of subjects: 41
Study: 26200563

Group type: EXPERIMENTAL
Intervention: New BNR method using deep dorsal stitch
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard 'tennis racket' BNR
Number of subjects: 84
Study: 24124744

Group type: EXPERIMENTAL
Intervention: 1% methylene blue or nanogate carbon injected into tumor bed
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 77
Study: 20619727

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17687273

Group type: EXPERIMENTAL
Intervention: Terbinafine pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voriconazole pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 0
Study: 17068687

Group type: EXPERIMENTAL
Intervention: Corrected bladder neck movement >=10 mm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Corrected bladder neck movement <10 mm
Number of subjects: 48
Study: 12600250

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-weight-bearing exercise
Number of subjects: 80
Study: 11196405

Group type: EXPERIMENTAL
Intervention: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent, containing NaF 0.25 mg, xylitol 159 mg, sorbitol 153 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fluoride tablets (Fludent) crushed in food
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fall‐Asleep Pacifier (FAP) with fluoride tablets (Fludent)
Number of subjects: 122
Study: 8620132

Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 4684

Group type: COMPARATOR
Intervention: Usual accident and emergency staff
Number of subjects: 4684
Study: 1460493

Group type: EXPERIMENTAL
Intervention: Dipyridamole supplemented with exercise protocols
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Walking in place and Bruce treadmill exercise at Stage 0 or 0.5
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bruce Stage 1 exercise supplementation
Number of subjects: 120
Study: 28734907

Group type: EXPERIMENTAL
Intervention: Oral second generation antipsychotic
Number of subjects: 221

Group type: COMPARATOR
Intervention: Long-acting injectable risperidone microspheres
Number of subjects: 221
Study: 27179374

Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (MLE)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Lateral episiotomy (LE)
Number of subjects: 648
Study: 25020050

Group type: EXPERIMENTAL
Intervention: 1 dose MenC‐TT at 3 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1 or 2 doses of MenC‐CRM197
Number of subjects: 110

Group type: COMPARATOR
Intervention: No primary MenC doses
Number of subjects: 110
Study: 22251050

Group type: EXPERIMENTAL
Intervention: Masked International Affective Picture System (IAPS) pictures eliciting disgust or fear as primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facial expressions of disgust or fear as primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Words 'disgust' or 'fear' as primes
Number of subjects: 0
Study: 20397594

Group type: EXPERIMENTAL
Intervention: Perfect duty violations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imperfect duty violations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manipulated information about an agent's mental intentions
Number of subjects: 0
Study: 18415829

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 microg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 microg BID
Number of subjects: 0
Study: 16750059

Group type: EXPERIMENTAL
Intervention: Interferon-alpha and ribavirin for 48 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Interferon-alpha and ribavirin for mild disease
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b and ribavirin
Number of subjects: 98
Study: 14572126

Group type: EXPERIMENTAL
Intervention: Oral CPAP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 21
Study: 10744089

Group type: EXPERIMENTAL
Intervention: Irinotecan plus fluorouracil and calcium folinate (irinotecan group)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Fluorouracil and calcium folinate alone (no-irinotecan group)
Number of subjects: 387
Study: 8624384

Group type: EXPERIMENTAL
Intervention: Empiric broad-spectrum antibiotic therapy
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Modification of antibiotic therapy
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Glycopeptides
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Systemically active antifungals
Number of subjects: 1951
Study: 1307733

Group type: EXPERIMENTAL
Intervention: Lippes Loop D
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: copper T 380
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Cu T 200 and 220
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: copper 7
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: T IUDs liberating progesterone or progestagens (Nor 8; Nor 2; Net 10)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: non‐steroid anti‐inflammatory prostaglandin synthesis' inhibitors (500 mg of mefenamic acid or 250 mg of Naproxen thrice daily for 5 days)
Number of subjects: 319
Study: 6365352

Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 0
Study: 31257924

Group type: EXPERIMENTAL
Intervention: Sitting height percentiles (3rd, 10th, 25th, 50th, 75th, 90th, and 97th) computed using LMS chartmaker
Number of subjects: 7961

Group type: EXPERIMENTAL
Intervention: Sitting height to height (StH:Ht) ratio
Number of subjects: 7961
Study: 30134240

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow's milk protein-based formula (pHF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Extensively hydrolyzed cow's milk protein-based formula (eHF)
Number of subjects: 25
Study: 26872294

Group type: EXPERIMENTAL
Intervention: SIT + MA (moderate-intensity walking every 20 min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SIT + LA (light-intensity walking every 20 min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 13
Study: 25204295

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 839

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no MBP)
Number of subjects: 839
Study: 22268969

Group type: EXPERIMENTAL
Intervention: 40 mg of isoflavones daily from Soylife 40
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 21072892

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein
Number of subjects: 140

Group type: COMPARATOR
Intervention: Regular liver treatment only
Number of subjects: 140
Study: 18765394

Group type: EXPERIMENTAL
Intervention: Percutaneous continuous aortic flow augmentation (flow ≤1.5 L/min for up to 96 hours) plus medical therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 168
Study: 15772912

Group type: EXPERIMENTAL
Intervention: Alvimopan 1 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 14764418

Group type: EXPERIMENTAL
Intervention: Cohen-Mansfield Agitation Inventory (CMAI-long form)
Number of subjects: 140
Study: 10411798

Group type: EXPERIMENTAL
Intervention: Esclim 0.025 mg 17beta‐estradiol per 24 hours
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Esclim 0.050 mg 17beta‐estradiol per 24 hours
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Esclim 0.100 mg 17beta‐estradiol per 24 hours
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 7551400

Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both positions (supine and semirecumbency)
Number of subjects: 15
Study: 2373139

Group type: EXPERIMENTAL
Intervention: 30 mg suppository
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3 x 5 mg oral tablets
Number of subjects: 12
Study: 7442081

Group type: EXPERIMENTAL
Intervention: Oral diazoxide (median dose 400 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral minoxidil (median dose 17.5 mg/d)
Number of subjects: 11
Study: 31725467

Group type: EXPERIMENTAL
Intervention: Method 1 (Scopus author affiliation data)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Method 2 (Corresponding author's description of disciplines)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Method 3 (Corresponding author's definition of disciplinarity)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of methods 1 and 3
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of methods 2 and 3
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall trend from 2005 to 2015
Number of subjects: 100
Study: 30662058

Group type: EXPERIMENTAL
Intervention: Saphenous vein Y-graft
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27996371

Group type: EXPERIMENTAL
Intervention: Combined maneuver (injection of local anesthesia at the incision site, low‐pressure pneumoperitoneum, active gas suction, and pulmonary recruitment)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined maneuver
Number of subjects: 51

Group type: COMPARATOR
Intervention: No maneuvers (control group B)
Number of subjects: 51
Study: 26472419

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for double contour (DC) lesions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for tophus lesions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for aggregates
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound examination for erosions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for tophus lesions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for DC lesions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for erosions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for aggregates
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for tophus lesions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for erosions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for aggregates
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interobserver reliability for DC lesions
Number of subjects: 8
Study: 23713604

Group type: EXPERIMENTAL
Intervention: 2g oral intradialytic protein (group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 29g oral intradialytic protein (group 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Red meat snack supplementation (group 1)
Number of subjects: 14
Study: 22033001

Group type: EXPERIMENTAL
Intervention: Bone wax (Group 1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Spongostan (Group 2)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Spongostan applied and removed after 10 minutes (Group 3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (Group 4) - no haemostatic agent applied
Number of subjects: 66
Study: 18265981

Group type: EXPERIMENTAL
Intervention: New Technique (NT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional Technique (CT)
Number of subjects: 76
Study: 17823678

Group type: EXPERIMENTAL
Intervention: Traditional syringe delivery system using a standardized 2-cartridge reloading and reinjection technique
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Computer-controlled delivery system using a technique whereby the second cartridge was reloaded without having to remove the needle from the injection site
Number of subjects: 35

Group type: COMPARATOR
Intervention: Computer-controlled delivery system
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional syringe delivery system
Number of subjects: 35
Study: 15867022

Group type: EXPERIMENTAL
Intervention: Momentary Sampling (MS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diaries
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Retrospective Self-Report
Number of subjects: 10
Study: 12225443

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Programme (CRP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 43
Study: 9444687

Group type: EXPERIMENTAL
Intervention: Level-of-care decision-support tool
Number of subjects: 1034
Study: 7600855

Group type: EXPERIMENTAL
Intervention: Glucagon and diazepam (active substances)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 2213284

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 0
Study: 36118

Group type: EXPERIMENTAL
Intervention: 0.5 mg prenalterol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg prenalterol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 31125609

Group type: EXPERIMENTAL
Intervention: Opioid administration
Number of subjects: 299
Study: 28229390

Group type: EXPERIMENTAL
Intervention: 0.2 g·kg‐1 body mass NaHCO3 (SBC2a and b)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 body mass NaHCO3 (SBC3a and b)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control treatments (CON1a and b)
Number of subjects: 15
Study: 26124726

Group type: EXPERIMENTAL
Intervention: MCTd (Metacognitive training for delusions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study: 23587162

Group type: EXPERIMENTAL
Intervention: Peretinoin 300 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peretinoin 600 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peretinoin (both dosages)
Number of subjects: 12
Study: 21768625

Group type: EXPERIMENTAL
Intervention: Cemented polyethylene acetabular component
Number of subjects: 55

Group type: COMPARATOR
Intervention: Monobloc trabecular metal acetabular component
Number of subjects: 55
Study: 19820031

Group type: EXPERIMENTAL
Intervention: GHR blockade (pegvisomant)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 17078309

Group type: EXPERIMENTAL
Intervention: Nicotine (NIC) using a 21-mg transdermal patch
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PL) treatment
Number of subjects: 11
Study: 15020363

Group type: EXPERIMENTAL
Intervention: Femoral neck fractures
Number of subjects: 807

Group type: COMPARATOR
Intervention: Control group without fractures
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Spine fractures
Number of subjects: 807
Study: 10762505

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) treatment during the first night
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NCPAP treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched without sleep-related breathing disorders)
Number of subjects: 10
Study: 8960425

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (HBW 023) bolus of 0.07, 0.1, 0.2 or 0.4 mg.kg‐1 followed by infusion of 0.05, 0.06, 0.1 or 0.15 mg.kg‐1 over 48 h
Number of subjects: 40
Study: 2060177

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 24
Study: 6303871

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: 500 mg griseofulvin daily
Number of subjects: 50
Study: 30768449

Group type: EXPERIMENTAL
Intervention: Orthotic intervention combined with scoliosis specific exercise (OE group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthotic intervention only (OI group)
Number of subjects: 0
Study: 27122063

Group type: EXPERIMENTAL
Intervention: Little cigar (Winchester)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cigarette (own brand)
Number of subjects: 21
Study: 27649689

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 25099645

Group type: EXPERIMENTAL
Intervention: NCE01
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NCE02
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NCE03
Number of subjects: 0
Study: 22905660

Group type: EXPERIMENTAL
Intervention: Structured workbook with self-monitoring exercises
Number of subjects: 51

Group type: COMPARATOR
Intervention: Structured workbook without self-monitoring exercises
Number of subjects: 51
Study: 20919542

Group type: EXPERIMENTAL
Intervention: Combination of a hypercalorie formula and a fiber‐containing formula with erythromycin stimulation within the first 3 days.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isocalorie formula (control group).
Number of subjects: 58
Study: 18416614

Group type: EXPERIMENTAL
Intervention: Rely-a-Bond
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transbond
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: M-Bond
Number of subjects: 15

Group type: COMPARATOR
Intervention: All adhesive systems
Number of subjects: 15
Study: 15811141

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 12425502

Group type: EXPERIMENTAL
Intervention: Antibiotic prescription for purulent rhinorrhea of less than 10 days' duration; 51 out of 149 pediatricians (34%) prescribed antibiotics.
Number of subjects: 149

Group type: COMPARATOR
Intervention: Actual practice habits of pediatricians; review of office records.
Number of subjects: 149
Study: 10479837

Group type: EXPERIMENTAL
Intervention: Forced‐air active warming (group active, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Passive thermal insulation with reflective blankets (group passive, n = 25)
Number of subjects: 50
Study: 8630539

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 73
Study: 2210865

Group type: EXPERIMENTAL
Intervention: IgG-anti-LPS therapy (more than 65 micrograms/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (less than 12.5 micrograms/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IgG-anti-LPS therapy
Number of subjects: 18
Study: 412207

Group type: EXPERIMENTAL
Intervention: Atenolol = 50 mg t.d.s.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methyl dopa = 250 mg t.d.s.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propanolol = 40 mg t.d.s.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reserpine = 0.2 mg t.d.s.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control = no tablets
Number of subjects: 60
Study: 30844114

Group type: EXPERIMENTAL
Intervention: Computer-based self-learning (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Didactic training (n = 8)
Number of subjects: 16
Study: 28092069

Group type: EXPERIMENTAL
Intervention: Antimuscarinics and beta‐3 adrenergic agonists (alone or in combination with standard BPE/BPO therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard alpha‐adrenergic blockade and 5‐alpha reductase inhibitor therapy
Number of subjects: 0
Study: 25358450

Group type: EXPERIMENTAL
Intervention: Tesamorelin 1 mg administered daily for 14 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tesamorelin 2 mg administered daily for 14 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tesamorelin (1 or 2 mg) administered daily for 14 days
Number of subjects: 38
Study: 23303891

Group type: COMPARATOR
Intervention: Patient information leaflet control group
Number of subjects: 3562

Group type: EXPERIMENTAL
Intervention: Five minutes of structured brief advice
Number of subjects: 3562

Group type: EXPERIMENTAL
Intervention: 20 minutes of brief lifestyle counselling
Number of subjects: 3562
Study: 21263369

Group type: EXPERIMENTAL
Intervention: Trusting relationship with medical staff
Number of subjects: 204

Group type: COMPARATOR
Intervention: Length of stay in the intensive care unit
Number of subjects: 204

Group type: COMPARATOR
Intervention: Family's emotional reactions
Number of subjects: 204
Study: 19501215

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg bid coadministered with ethinylestradiol/norethindrone
Number of subjects: 30
Study: 23051684

Group type: COMPARATOR
Intervention: Rivastigmine patch monotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Memantine plus rivastigmine patch
Number of subjects: 206
Study: 16430026

Group type: EXPERIMENTAL
Intervention: Citalopram-ratiopharm film-coated tablets (test preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tablets of a reference preparation (control)
Number of subjects: 20
Study: 12856477

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (INFB-1b) therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal subjects (Control group)
Number of subjects: 15
Study: 9856290

Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive-Behaviour Therapy (MACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 7620474

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2711919

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for 2 weeks
Number of subjects: 10
Study: 889650

Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg/kg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Althesin 0.055 ml/kg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pethidine 0.7 mg/kg after intubation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Saline after intubation
Number of subjects: 157